women with advanced cervical cancer â the most common cancer afflicting young women â are to get the first officially approved new treatment for a decade
the drug plus chemotherapy has now been licensed by european regulators
it has been available in england via the cancer drugs fund since last march pending licensing
the drug âs use was accelerated by the us food and drug administration which approved avastin plus chemotherapy for advanced cervical cancer in august 2014
nearly 3,000 women are diagnosed with cervical cancer in the britain each year , and it kills around 1,000 women
cervical cancer , which is cancer of the neck of the womb , is the most common cancer in women aged 35 and under
cervical cancer : reality tv star jade goody died in 2009 aged 27 after a very public battle with the disease avastin , which is also known as bevacizumab and widely used in patients with bowel cancer , is the first new treatment since the chemotherapy drug topotecan was approved in 2006
dr mary mccormack , consultant clinical oncologist at university college hospital , said â cervical cancer is the most commonly diagnosed cancer in younger women
to date , prognosis for women who receive a late - stage diagnosis of cervical cancer has often been poor
â trial findings show avastin combined with chemotherapy can extend the lives of women with advanced cervical cancer by 26 per cent compared with chemotherapy alone